Management

Sarah Almond

VP Translational Biology

Sarah Almond

VP Translational Biology

Nearly 30 years of drug discovery and translational biology experience.

Led biology and pharmacology teams at Astellas, Mission Therapeutics, Charles River Laboratories, Takeda, AstraZeneca, and Merck.

Advanced multiple small-molecule programs from discovery through to clinical development.

David Brocklebank, MRPharmS, DipClinSci

Director of Clinical Operations

David Brocklebank, MRPharmS, DipClinSci

Director of Clinical Operations

Over 37 years’ pharma & biotech experience.

Industry experience across all stages of clinical development including senior roles in Clinical Operations and Project Management at Shire Pharmaceuticals, Kissei Pharma Europe, Mitsubishi Tanabe, Takeda and Ono Pharma UK.

Prior biotech start-up experience as Director, Clinical Operations at Outpost Medicine Ltd (2016-2018) and Kynos Therapeutics Ltd (2022-2024).

Alex Eagleson, ACMA, CGMA

Financial Controller

Alex Eagleson, ACMA, CGMA

Financial Controller

Over 20 years’ accounting and finance experience.

Prior FC roles within the technological and engineering sectors.

Leigh Gullon

Executive Assistant

Leigh Gullon

Executive Assistant

Over 18 years' experience supporting C-Suite Executives.

Prior Executive Assistant roles in the Pharmaceutical and Learning and Development sectors.

Grant Hawthorne

COO and Co-founder

Grant Hawthorne

COO

Over 25 years’s finance and operations experience.

Biotech experience as CFO at Myricx Bio, Alchemab Therapeutics and Camphos Therapeutics and COO at Auspherix Ltd. (2014-18).

Vad Lazari, PhD

VP Biology

Vad Lazari, PhD

VP Biology

Two decades of drug discovery experience.

Industry experience gained at Charles River, Pfizer and BioFocus DPI .

Led project teams in multiple areas including neurodegenerative disease, rare diseases and oncology, delivering preclinical and clinical candidates in a range of modalities.

Marina Lizio, PhD

Bioinformatician

Marina Lizio, PhD

Bioinformatician

20 years computational experience turning large-scale, complex -omics data into biological insights.

Industry experience as Principal Scientist at Cerevance Ltd, advancing data-driven approaches to disease biology and therapeutic target discovery.

Professor Seth Masters, PhD

VP Discovery Biology

Professor Seth Masters, PhD

VP Discovery Biology

Over 20 years’ academic research in innate immunity.

Discovery of a new pathological mechanism in ALS implicating the mPTP.

Head of the Hudson Institute - Centre for Innate Immunity and Infectious Disease at Monash Health, Melbourne, Australia.

Neil Miller, PhD

CEO and Co-founder

Neil Miller, PhD

CEO

Over 25 years’ pharma & biotech experience.

Industry experience as Senior Director and Head of Chemistry, DMPK and External Discovery at GSK Singapore.

Prior biotech experience as CEO at Auspherix Ltd (2015-18).

Lorraine Mumtaz

Clinical Operations Manager

Lorraine Mumtaz

Clinical Operations Manager

Over 15 years of clinical trials management experience spanning both academia and biotech.

Proven track record in early-phase, First-in-Human (FiH) trials across a range of therapeutic indications.

Driven to deliver innovative therapies to patients in need.

Kathryn Oliver

Director of Project Management

Kathryn Oliver

Director of Project Management

Over 15 years' experience in biotech drug discovery and development.

A medicinal chemist by training, evolved into project management to help deliver novel therapeutics to patients with a high unmet need.

Gilles Ouvry, PhD

VP Chemistry

Gilles Ouvry PhD

VP Chemistry

20 years of international medicinal chemistry experience.

Industry as VP, Discovery Chemistry Evotec and at Galderma, AstraZeneca and SCYNEXIS.

Has worked on over 20 drug discovery projects generating multiple pre-clinical and four clinical stage development candidates.

Richard Rutter, PhD

CSO and Co-founder

Richard Rutter, PhD

CSO

Over 20 years’ pharma & biotech experience.

Industry experience as Director and Head of Biology at GSK Singapore; Senior Research Biologist at MSD.

Prior biotech experience as CSO at Ausperix Ltd (2016-18).

Claus Sundgreen, MD

CMO

Claus Sundgreen, MD

Chief Medical Officer

Over 25 years’ clinical leadership experience, with particular expertise in ALS.

Senior medical leadership positions across biotechnology and pharmaceutical companies in Europe and the United States, including at HD Immune, Abcuro, VectorY, Tikomed, Orphazyme, uniQure and NeuroSearch. His earlier career included Medical Director roles at Schering Plough and Nycomed, following 10 years in medical practice.

Paul Thompson, PhD

CDO

Paul Thompson, PhD

CDO

Over 25 years’ experience in translational research, early clinical development, and pharma R&D, with a focus predominantly on neurology.

Senior biotech and pharma experience at Mission Therapeutics, ONO Pharma UK, GSK.

Board

  • Francesco Draetta

    Investor Non Executive Director

  • Mathias Frederikson, PhD

    Investor Non Executive Director

  • Georgia Frost, PhD

    Investor Non Executive Director

  • Charlotte Kremers, PhD

    Investor Non Executive Director

  • Neil Miller, PhD

    CEO and Executive Director

  • Claudio Nessi, PhD

    Investor Non Executive Director

  • Jonathan Savidge, PhD

    Chair and Non Executive Director

  • Laurence Barker, PhD

    Investor Observer

  • Pablo Cironi, PhD

    Investor Observer

  • Professor David T. Dexter, PhD

    Investor Observer

  • Izzie Fuller

    Investor Observer

  • Hakan Goker, PhD

    Investor Observer

  • Saoussen Ben Halima, PhD

    Investor Observer

  • Katherine Jackman, PhD

    Investor Observer

  • Florian Muellershausen, PhD

    Investor Observer

SAB

  • James Summers, PhD

    SAB Chair

  • Melanie Leitner, PhD

    SAB Member

  • Kalpana Merchant, PhD

    SAB Member

  • Stevan Djuric, PhD

    SAB Member

  • Professor David T. Dexter, PhD

    Special Advisor on Parkinson’s